101 related articles for article (PubMed ID: 24047790)
1. [A case on hemodialysis with castration-resistant prostate cancer which responded to combination chemotherapy with docetaxel and prednisolone].
Ito H; Inamura S; Taga M; Tsuchiyama K; Kusukawa N; Oyama N; Akino H; Yokoyama O
Gan To Kagaku Ryoho; 2013 Sep; 40(9):1245-7. PubMed ID: 24047790
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of docetaxel and prednisolone for castration-resistant prostate cancer: a multi-institutional retrospective study in Japan.
Fukuta F; Kitamura H; Yanase M; Taguchi K; Takahashi A; Kunishima Y; Miyake M; Adachi H; Itoh N; Hirose T; Takagi S; Miyao N; Matsukawa M; Shigyo M; Masumori N
Jpn J Clin Oncol; 2015 Jul; 45(7):682-7. PubMed ID: 25862824
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
4. NICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen.
Dyer M; Rinaldi F; George E; Adler AI
Lancet Oncol; 2012 Aug; 13(8):762-3. PubMed ID: 23024987
[No Abstract] [Full Text] [Related]
5. [Successful treatment with docetaxel and prednisolone for paxlitaxel and carboplatin-resistant prostate cancer].
Kusukawa N; Ishida H; Tanase K; Ito H; Aoki Y; Ooyama N; Akino H; Yokoyama O
Hinyokika Kiyo; 2013 May; 59(5):301-4. PubMed ID: 23719139
[TBL] [Abstract][Full Text] [Related]
6. [Scleroderma-like skin sclerosis induced by docetaxel chemotherapy for hormone refractory prostate cancer: a case report].
Maehana T; Mizuno T; Muto M; Nishiyama N; Yanase M
Nihon Hinyokika Gakkai Zasshi; 2010 Sep; 101(6):726-9. PubMed ID: 20954379
[TBL] [Abstract][Full Text] [Related]
7. Low-dose prednisolone in first-line docetaxel for patients with metastatic castration-resistant prostate cancer: is there a clinical benefit?
Kongsted P; Svane IM; Lindberg H; Daugaard G; Sengeløv L
Urol Oncol; 2015 Nov; 33(11):494.e15-20. PubMed ID: 26254696
[TBL] [Abstract][Full Text] [Related]
8. [A case of hormone-refractory prostate cancer (HRPC) with tumor fever responding to docetaxel plus prednisolone therapy].
Miura N; Numata K; Azuma K; Hashine K; Sumiyoshi Y
Gan To Kagaku Ryoho; 2006 Jun; 33(6):841-4. PubMed ID: 16770110
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcome of docetaxel plus prednisolone for metastatic castration-resistant prostate cancer in Korea.
Cho IC; Joung JY; Seo HK; Chung J; Park WS; Lee KH
J Cancer Res Ther; 2014; 10(2):251-7. PubMed ID: 25022374
[TBL] [Abstract][Full Text] [Related]
10. [Long-term disease stabilization by docetaxel plus estramustine for castration-resistant prostate cancer : report of a case].
Kageyama S; Iwaki H; Masuda Y; Yoshida T; Narita M; Okada Y
Hinyokika Kiyo; 2011 Apr; 57(4):203-7. PubMed ID: 21646852
[TBL] [Abstract][Full Text] [Related]
11. [An elderly hemodialytic case of recurrent esophageal cancer given combination chemotherapy with docetaxel and nedaplatin who showed temporal relief of swallowing disturbance].
Miura T; Hosojima Y; Nakamura J; Yamada S; Nakazawa Y; Ozeki Y; Miura T; Yanagi M; Yamazaki H; Takahashi T
Gan To Kagaku Ryoho; 2010 May; 37(5):883-5. PubMed ID: 20495320
[TBL] [Abstract][Full Text] [Related]
12. Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.
Kwak C; Wu TT; Lee HM; Wu HC; Hong SJ; Ou YC; Byun SS; Rhim HY; Kheoh T; Wan Y; Yeh H; Yu MK; Kim CS
Int J Urol; 2014 Dec; 21(12):1239-44. PubMed ID: 25099185
[TBL] [Abstract][Full Text] [Related]
13. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel-prednisolone combination therapy for Japanese patients with hormone-refractory prostate cancer: a single institution experience.
Miura N; Numata K; Kusuhara Y; Shirato A; Hashine K; Sumiyoshi Y
Jpn J Clin Oncol; 2010 Nov; 40(11):1092-8. PubMed ID: 20587613
[TBL] [Abstract][Full Text] [Related]
15. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer.
Heck MM; Thalgott M; Retz M; Wolf P; Maurer T; Nawroth R; Hatzichristodoulou G; Gschwend JE; Kübler H
BJU Int; 2012 Dec; 110(11 Pt B):E635-40. PubMed ID: 22889368
[TBL] [Abstract][Full Text] [Related]
16. Editorial comment on: Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study.
Bracarda S
Eur Urol; 2007 Dec; 52(6):1698-9. PubMed ID: 17306444
[No Abstract] [Full Text] [Related]
17. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.
Kellokumpu-Lehtinen PL; Harmenberg U; Joensuu T; McDermott R; Hervonen P; Ginman C; Luukkaa M; Nyandoto P; Hemminki A; Nilsson S; McCaffrey J; Asola R; Turpeenniemi-Hujanen T; Laestadius F; Tasmuth T; Sandberg K; Keane M; Lehtinen I; Luukkaala T; Joensuu H;
Lancet Oncol; 2013 Feb; 14(2):117-24. PubMed ID: 23294853
[TBL] [Abstract][Full Text] [Related]
18. [Docetaxel-based combination chemotherapy for castration-resistant prostate cancer].
Urakami S; Shiina H; Igawa M
Nihon Rinsho; 2011 Jun; 69 Suppl 5():531-7. PubMed ID: 22208039
[No Abstract] [Full Text] [Related]
19. [Palliative anti-cancer chemotherapy is safely executable in a hemodialytic patient with unresectable advanced gastric cancer].
Miura T; Hosojima Y; Nakamura J; Yamada S; Nakazawa Y; Ozeki Y; Miura T; Yanagi M; Yamazaki H; Takahashi T
Gan To Kagaku Ryoho; 2011 Mar; 38(3):453-6. PubMed ID: 21403453
[TBL] [Abstract][Full Text] [Related]
20. [A case of castration-refractory prostate cancer showing marked decrease of serum PSA level after zoledronic acid treatment with estramustine phosphate and prednisolone].
Hirayama Y; Ito Y; Kanamaru T; Sonoda T; Aoyama M; Nakamura N; Kawamura M
Gan To Kagaku Ryoho; 2011 Mar; 38(3):485-7. PubMed ID: 21403461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
